Foodie Pundit

Breast Milk Study Quietly Added to FDA File

FDA added a 2022 study on acetaminophen in human milk to a public docket; it is background material with no immediate policy change.

By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

milk carton grocery dairy photograph for this story

Key points

  • FDA added a 2022 pediatric study about acetaminophen in breast milk to a public docket on 2026-08-19.
  • The entry is background material, not a new rule or guidance, so it does not change labels or grocery shelves right now.
  • The record ties into the food chain at the point where human milk is nutrition, but the path to consumer prices or menus is indirect.
  • No lobbying money or filer is listed in the docket entry; the record shows none disclosed.
  • If you are breastfeeding and worried about medication, talk to your pediatrician; the docket just flags research, it does not give medical advice.

Early morning, you might be rinsing a pump part in the kitchen sink while a barista-made iced coffee hits your timeline, or you might be scanning the infant formula aisle because your partner went back to work and you are deciding whether to keep breastfeeding. Either way, food is involved: what ends up in a baby bottle or in human milk is food, and federal agencies treat some research about that milk as part of their decision files.

On August 19, 2026, an entry appeared in an FDA public comment file that names a specific pediatric study about acetaminophen and other foreign chemicals in human milk. The government did not issue a new rule or a directive. It logged that 2022 study as supporting background material in a docket the FDA is maintaining. That government action, a filing in a docket, touches the milk-as-food link in the food chain, specifically the health and safety side of what infants consume.

On 2026-08-19 the U.S. Food and Drug Administration, through its public docket system on regulations. gov, added a piece of supporting material titled Reference 10. The item is a citation to a 2022 article in the Journal of Pediatrics: Santoro KL, Yakah W, Singh P, Ramiro-Cortijo D, Medina-Morales E, Freedman SD, et al.

Acetaminophen and xenobiotic metabolites in human milk and the development of bronchopulmonary dysplasia and retinopathy of prematurity in a cohort of extremely preterm infants. J Pediatr. 2022;244:224-229.

2022.01.030. PMID:35093319; PMCID:PMC9152735.

Translate the jargon: a docket is a public comment file where the government collects documents and feedback related to a regulatory matter. Supporting and related material means this citation was submitted as background or context for whatever the FDA is collecting in docket FDA-2026-P-9431. The record itself is not a new FDA finding; it is a reference being kept in the file.

The record lists the article as background material. It does not include any additional analysis from the FDA in that filing, and it does not publish new data. The citation includes a DOI, the PubMed ID or PMID, and a PMCID, which means the full article is available in the free PubMed Central archive.

The record lists no money exchanged, no lobbyist disclosures, and it names the agency in charge of the docket as the FDA. The entry also shows a place listed as SD, but the docket entry does not explain what SD stands for in this context.

Short answer, this record touches the food chain at the point where human milk is considered food. Human milk is part of the infant feeding and food safety ecosystem. The documented path in the record is narrow and procedural: a peer reviewed pediatric study was cited and added as background material to an FDA public docket.

Beyond that, the document on Regulations. gov does not say the FDA is using the study to change labeling, issue guidance, or alter any policy that would immediately affect grocery prices, restaurant menus, or the items stocked at a convenience store.

The plausible, documented downstream links are these. The FDA, when it compiles evidence in a docket, may be preparing for a rulemaking, a safety communication, a product review, or an advisory. All of those agency actions, if they happen, can influence what parents choose to buy or what product makers are required to say on labels.

For example, if the FDA were to use this and other studies to support new guidance about medication use while breastfeeding, that could influence clinical recommendations and parental decisions about feeding. That could change demand for formula, lactation supplements, over the counter medications, or services like lactation consulting; those are grocery and household spending links.

But the record itself does not document any of that. It only documents that the FDA has this 2022 study in the public file for docket FDA-2026-P-9431. The path from that citation to your grocery bill is therefore indirect and contingent on future agency action that the record does not specify.

The decider listed in this record is the Food and Drug Administration, the federal agency with responsibilities for regulating food safety, drugs, medical devices, and related public health communications. The FDA is the keeper of docket FDA-2026-P-9431, which is the public comment file where this reference was submitted.

The record itself cites the authors of the 2022 Journal of Pediatrics article. Those researchers, led by Santoro KL and colleagues, produced the peer reviewed study that is now listed as Reference 10. The FDA entry does not say who submitted the citation to the docket; it could be the agency, an outside researcher, an advocacy group, or a private party. The docket entry does not include a sponsoring organization, a committee, or a named filer for this specific reference.

The record also lists zero money and no lobbying disclosures. When public filings include lobbying influence, the law requires naming the client, the registrant, the amount, and the agencies targeted. This record shows none of that. In short, the people who wrote the study are in the file as a source; the FDA is the agency holding the file; the record does not say who placed the paper in the docket or why.

Two small but meaningful details sit buried in the citation that matter to anyone who does want to read up. First, the reference appears in the docket as Reference 10, under Supporting and Related Material labeled Background Material. That classification matters because background material usually provides context rather than being the centerpiece of a regulatory decision.

If the FDA intended to rely on this single study as a primary basis for rulemaking, the citation would likely be accompanied by internal analyses, agency memos, or other supporting documents. The Regulations. gov entry contains none of that.

Second, the citation includes a PMCID. PMCID means the paper is available in the PubMed Central free archive. That matters because anyone, including parents, clinicians, and reporters, can access the full study without a paywall and check what the authors actually measured, how they analyzed it, and what conclusions they drew. The docket file does not summarize the paper, nor does it extract results or signal that the FDA has accepted any conclusions from the study.

Also worth noting, the paper title links three concepts that are technical but relevant. Acetaminophen is the common over the counter pain and fever medicine many people know as Tylenol. Xenobiotic metabolites means chemical byproducts of foreign substances that can show up in milk; xenobiotic is a scientific term for a chemical that is not naturally produced by the body.

Bronchopulmonary dysplasia is a chronic lung condition in infants, especially preterm babies. Retinopathy of prematurity is an eye condition that can affect premature infants. The 2022 study examined how traces of acetaminophen and other xenobiotic metabolites in human milk related to those neonatal conditions in a cohort of extremely preterm infants.

The docket entry does not say whether the study found a causal link, an association, or no link; it only records the citation itself.

This is not the kind of federal filing that changes a restaurant menu or shifts what the grocery store stocks tomorrow. The docket entry is a citation, and its immediate relevance is mostly to clinicians, researchers, and policymakers who track infant health and breastfeeding safety. That said, if you are a parent, a caregiver, or a partner of someone breastfeeding, this is a reminder that medication use while nursing is an area where evidence is actively collected and discussed at the federal level.

If you are feeding an infant and wondering what to do about acetaminophen, the record does not offer medical guidance. The practical move is to consult your pediatrician or a lactation consultant before changing medication routines. If you work at a restaurant or a grocery store, nothing in this filing requires changing food handling or menu items. If you are buying formula because you are worried, understand that this entry alone does not justify a switch; the record provides no policy change or regulatory action that would mandate changes in product labeling or availability.

The record names the agency that is maintaining the file, the FDA. It also gives the docket identifier FDA-2026-P-9431 and a filing date of 2026-08-19 for this supporting reference. The docket entry does not state a comment close date, an effective date, or any next milestone. Therefore the next concrete date from this record is not available.

If you want to track whether this citation turns into a policy action, the practical step is to watch the FDA docket FDA-2026-P-9431 on Regulations.gov for any further filings, agency memos, or notices that state a proposed rule, a request for comments, or a safety communication. The public docket system will list comment deadlines or new materials if the FDA takes a next step. As of the record date, the entry is background material only.

The government did not ban, require, or recommend anything in this filing. It added a 2022 peer reviewed pediatric study about acetaminophen and xenobiotic metabolites in human milk to an FDA public docket as background material. That ties into the food chain at the point where human milk is treated as nutrition and a vector for chemical exposures, but the record does not link this citation to any immediate changes in labeling, product availability, or consumer prices. There are no lobbying disclosures tied to this entry, and the file provides no next date for action.

If you are a new parent or someone making decisions about infant feeding, this is a cue that the matter is being watched in federal records. It is not a signal to panic, change your shopping list, or stop breastfeeding. It is a prompt to ask your health care providers about medication use while nursing and to keep an eye on the FDA docket if you want to follow any future policy moves.

Sources and methodology

Reported from the public datasets below.

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

Permalink